Over the previous 10 months, a number of high-profile inventory splits helped animate an already energetic inventory market. One in every of them was that of the medical machine knowledgeable DexCom (DXCM -0.81%), which accomplished a 4-for-1 inventory cut up in June.
In fact, inventory splits do not essentially change the prospects of the corporate, and DexCom’s did little to jolt its inventory efficiency in 2022. The corporate’s shares have carried out roughly on par with the struggling inventory market this yr.
Can the healthcare firm rebound in 2023? Let’s look nearer at what DexCom has happening to seek out out.
Rolling out new gadgets
DexCom focuses on creating steady glucose monitoring (CGM) gadgets, which permit diabetes sufferers to maintain observe of their blood sugar ranges repeatedly. The corporate at the moment generates most of its cash from its G6 CGM machine, which comes with a sensor, a transmitter, and a touchscreen machine that shows blood glucose ranges.
Sufferers insert the sensor beneath the pores and skin and snap the transmitter into the sensor. The sensor lasts for 10 days. Whereas the G6 has been extremely profitable for DexCom, one of many key highlights for the corporate this yr has been the rollout of a few new CGM choices. The primary is the G7, the successor of its present crown jewel.
The G7 earned clearance in Europe earlier this yr. DexCom lately began the launch of this machine in a number of nations within the Outdated Continent. DexCom expects to obtain the inexperienced mild for the G7 within the U.S. by year-end. The corporate ought to provoke the machine’s launch within the nation subsequent yr.
DexCom’s different new machine is the DexCom ONE, which it has additionally launched in some elements of Europe, together with the U.Okay. What’s the distinction between all these choices? The G7 is an upgraded model of the G6. It has a quicker warm-up interval, which is the time it takes after setup earlier than glucose readings are readable on the accompanying touchscreen machine.
The G7 can also be 60% smaller — making it extra discreet — it has an built-in sensor and transmitter, making it less complicated to handle, and most significantly, it confirmed superiority in serving to diabetes sufferers obtain higher well being outcomes than the G6 in medical trials.
In contrast, the DexCom ONE doesn’t permit customers to share knowledge robotically with sure contacts, together with when blood glucose ranges fall beneath a sure threshold. Each the G6 and the G7 have this function. In trade, the DexCom ONE is cheaper than the corporate’s different choices.
The massive CGM alternative
DexCom’s latest CGM gadgets ought to assist it make additional headway within the CGM house subsequent yr. Within the U.S., a latest regulatory resolution may considerably improve the variety of individuals eligible for CGM protection within the nation, thereby widening the market. DexCom’s rollout of the G7 within the U.S. — if it earns clearance as the corporate expects — needs to be an necessary a part of the corporate’s progress technique within the U.S. in 2023.
DexCom can also be aggressively advertising and marketing its gadgets, and it has partnered with some high-profile celebrities to take action. DexCom’s G7, advertising and marketing efforts, and launch of the DexCom ONE ought to all assist it achieve extra adoption each inside and outdoors the U.S. As of final yr, CGM penetration within the U.S. diabetes kind 1 market was about 30%, leaving loads of room for growth.
The worldwide market additionally reveals loads of whitespace. And that is earlier than we account for the truth that the proportion of individuals with diabetes is on the rise, a development that’s projected to proceed for many years. Naturally, DexCom is not the one firm on this market. Its most notable competitor is Abbott Laboratories, whose FreeStyle Libre has additionally been profitable.
Even so, DexCom has established itself as one of many leaders in CGM, it continues to develop its income quickly, and its improvements ought to permit it to remain on par with Abbott and a few of its different friends on this business. Within the first 9 months of the yr, DexCom’s high line jumped by 19.7% yr over yr to $2.1 billion.
The corporate’s earnings per share got here in at $0.60 in comparison with the $0.54 within the year-ago interval. DexCom’s momentum within the CGM house ought to assist it ship glorious returns effectively past subsequent yr, making it a high healthcare inventory to purchase heading into the brand new yr.